OSUR News and Press, OraSure Technologies Inc. From 11/08/21

New Appointments Bring to the Company Significant Executive Leadership, Global Product Development, Public Health, and the Retail Pharmacy Market Experience BETHLEHEM, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-c...

Quidel has grown from a $15 stock in 2011 to $138 in 10 years. The recent boost in revenues from Covid-19 testing provides extra capital to deploy. With no long-term debt and exceptional revenue growth, the stock is a strong buy ahead of Q3 earnings. For further details see:...

The following slide deck was published by OraSure Technologies, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: OraSure Technologies, Inc. 2021 Q3 - Results - Earnings Call Presentation

Image source: The Motley Fool. Orasure Technologies Inc (NASDAQ: OSUR) Q3 2021 Earnings Call Nov 3, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Orasure Technologies Inc (OSUR) Q3 2021 Earnings Call Transcript

OraSure Technologies, Inc. (OSUR) Q3 2021 Earnings Conference Call November 3, 2021 5:00 PM ET Company Participants Scott Gleason – Interim Chief Financial Officer Stephen Tang – President and Chief Executive Officer Conference Call Participants Andrew Cooper – Raymond Ja...

OraSure Technologies (NASDAQ:OSUR): Q3 GAAP EPS of -$0.21 misses by $0.18. Revenue of $53.9M (+12.3% Y/Y) beats by $7.32M. Press Release For further details see: OraSure Technologies EPS misses by $0.18, beats on revenue

Third quarter revenue of $53.9 million grew 12% year-over-year; excluding COVID-19 product revenues, revenues for the quarter grew 37% from the prior year, demonstrating strong growth OraSure signs three major U.S. government contracts providing $205 million in government InteliSwab ...

OraSure Technologies (NASDAQ:OSUR) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, after market close. The consensus EPS Estimate is -$0.06 (-700.0% Y/Y) and the consensus Revenue Estimate is $46.58M (-3.0% Y/Y). Over the last 1 year, OSUR has beaten EPS estimates 50%...

OraSure Technologies (NASDAQ:OSUR) has gained ~9.0% in the pre-market after the company said that the FDA amended the previous Emergency Use Authorizations (EUA) issued for its InteliSwab COVID-19 rapid tests allowing it for single-use, at-home testing for symptomatic patients. According...

BETHLEHEM, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the EUA for its InteliSwab™ COVID-19 rapid tests has been amended by the ...